Artel, Inc. by Advanced Instruments news
Artel laboratory applications specialist Karlton Moore recently interviewed incoming SLAS Scientific Director Marshall Brennan for SLAS’ New Matter podcast series. Here’s a sample of the topics discussed in this episode:
Karlton Moore: “So how did you start off in the science field?”
Marshall Brennan: “I started out as a lab scientist with a BS in Chemistry, worked in the pharmaceutical industry, went to graduate school and did physical organometa
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the different types of quality control (QC) required for iPSCs with a focus on genomic stability assessment.
Stem cells have revolutionized cell-based therapeutics
The Society for Lab Automation and Screening (SLAS) has been, and continues to be, an invaluable resource for all scientists dealing with the fast-evolving presence of robotics in their work. New technology and new paradigms add considerable complexity to an already sophisticated field and having a professional society of peers available for collaboration and consultation is a priceless asset. SLAS will be presenting their
Advanced Instruments, the leading supplier in osmolality testing, announces the newest update to its clinical line of freezing point osmometers. The OsmoPRO® MAX is designed for clinical laboratories of all sizes seeking enhanced productivity through automation. The instrument uses innovative flow-through technology to eliminate manual pipetting and reduce the use of consumables, allowing testing to begin with the single push of a button.
The OsmoPRO MAX goes beyon
Following regulatory approval, Advanced Instruments, a wholly-owned subsidiary within Patricia Industries, has now completed its acquisition of Nova Biomedical, a global provider of analytical instruments and consumables for the biopharmaceutical and clinical markets.
The enterprise value amounts to USD 2.2bn. Patricia Industries has contributed USD 1.6bn in financing. The remainder of the enterprise value has been financed by external debt.
The combined company will now be na